Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
Sponsors
Chinese PLA General Hospital
Conditions
Acute Myeloid LeukemiaFirst Line TherapyRelapsed/Refractory Acute Myeloid Leukemia
Phase 2
Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia
CompletedNCT06068621
Start: 2023-03-01End: 2025-08-31Updated: 2026-01-20
Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
RecruitingNCT06084819
Start: 2023-08-01End: 2030-01-31Target: 200Updated: 2026-04-02
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
RecruitingNCT06928376
Start: 2024-04-18End: 2026-09-01Target: 160Updated: 2026-05-08